 Concurrent 100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RASMAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erascas addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 GLOBE NEWSWIRE Erasca, ... The post Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib appeared first on ForexTV... 